VAR continues to take centre stage as technology leaves its mark on World Cup

From Croatia's heartbreaking exit to group-stage qualification drama, a series of video reviews has helped shape the story of ...

Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential?

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. BridgeBio Oncology ...
Opinion

250 years later, American women still have to work for equality | Opinion

Upon America's 250th birthday, women have little to celebrate, and much work ahead to accomplish autonomy, respect and equality.
Finanznachrichten

BridgeBio Oncology Therapeutics, Inc.: BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs Announced publication in Cancer Discovery highlighting preclinical data demonstrating ...
The Globe and Mail

BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs Announced publication in Cancer Discovery highlighting preclinical data demonstrating ...
BioSpace

BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman

Pedro J. Beltran, PhD, a seasoned executive who previously served as Chief Scientific Officer of BBOT, will assume the position of Chief Executive Officer, bringing his extensive drug development ...
Yahoo Finance

BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Seeking Alpha

BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026

SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway ...
Finanznachrichten

BridgeBio Oncology Therapeutics, Inc.: BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic ...

BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors Updated Phase 1 clinical data are expected ...
WBOC

BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma

BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors SOUTH SAN FRANCISCO, Calif., April 20, ...
Investing

BBOT publishes preclinical data on panKRAS inhibitor BBO-11818

SOUTH SAN FRANCISCO - BridgeBio Oncology Therapeutics (NASDAQ:BBOT) announced today the publication of preclinical data on BBO-11818, a non-covalent inhibitor targeting KRAS in both active and ...